REMYELINATION. Although Annavex has said little about 2-73's remyelination properties, Dr Lisak and WSU have carried the torch there. I think Anavex and Biogen are still talking about MS but the problem is the large application footprint of 2-73. Go back and listen to Dr Sandrock (Biogen's chief scientist) final comments on the Lab Video. He says that Biogen would like to take the MS cure science and apply it to a wider group of neurodegenerative diseases....that would mean using 2-73's homeostasis properties to treat Alzheimers. And consequently, it would require Biogen to buy the whole 2-73 franchise. It is obvious that any current offer to Anavex in not substantial enough, but with success in any of the three trials, IMHO Biogen will have to significantly up the ante of fold. Then who among the "Big Boys" will call.
Market Data 
Markets 
